Gender issues in antiepileptic drug treatment

被引:30
|
作者
Perucca, Emilio [1 ,2 ]
Battino, Dina [3 ]
Tomson, Torbjorn [4 ]
机构
[1] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[2] C Mondino Natl Neurol Inst, Pavia, Italy
[3] Neurol Inst Carlo Besta Fdn, Dept Neurophysiol & Expt Epileptol, Epilepsy Ctr, Ist Ricovero & Cura Carattere Sci, Milan, Italy
[4] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
关键词
Epilepsy; Antiepileptic drugs; Gender; Pharmacokinetics; Pregnancy; Menopause; LAMOTRIGINE PLASMA-CONCENTRATIONS; SERUM CONCENTRATION/DOSE RATIO; POLYCYSTIC-OVARY-SYNDROME; MENSTRUAL-CYCLE; ORAL-CONTRACEPTIVES; CATAMENIAL EPILEPSY; PARTIAL SEIZURES; CLINICAL-TRIAL; VALPROIC ACID; YOUNG-WOMEN;
D O I
10.1016/j.nbd.2014.05.011
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The purpose of this review is to discuss gender-related aspects in the, pharmacokinetics, effects, selection and use of antiepileptic drugs (AED). In general, there are few known gender related differences in pharmacokinetics or efficacy of AEDs. Conversely, gender has a significant influence on the susceptibility to certain adverse effects, not the least those involving alterations in sex hormone metabolism. Particularly relevant are the teratogenic effects of AEDs, with important differences among AEDs in their potential to cause adverse effects on the fetus when used during pregnancy. Pregnancy can also markedly affect the pharmacokinetics of several AEDs, and dose adjustments are often needed during pregnancy to maintain seizure control. Some treatments that are used only by women, such as contraceptive steroids and hormone replacement therapy, can also interact with AEDs to an extent that may affect the utilization of both the AEDs and the other drug. (C) 2014 Published by Elsevier Inc.
引用
收藏
页码:217 / 223
页数:7
相关论文
共 50 条
  • [21] ANTIEPILEPTIC DRUG TREATMENT IN ELDERLY PATIENTS WITH EPILEPSY
    Theitler, J.
    Berkovitch, M.
    Gandelman-Marton, R.
    EPILEPSIA, 2016, 57 : 65 - 65
  • [22] Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment
    Bertilsson, L.
    Hatta, F. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S147 - S147
  • [23] Antiepileptic drug treatment strategies in neonatal epilepsy
    Hernan, A. E.
    Holmes, G. L.
    NEUROBIOLOGY OF EPILEPSY: FROM GENES TO NETWORKS, 2016, 226 : 179 - 193
  • [24] Agreement and correctness in adjusting antiepileptic drug treatment: A weed for rational drug treatment?
    Smeets, R
    Meinardi, H
    Talmon, J
    Hasman, A
    EPILEPSIA, 1999, 40 (06) : 763 - 768
  • [25] Bisphosphonates in the treatment of Antiepileptic drug induced osteoporosis
    Haneef, Zulfi
    Jacobson, Mercedes P.
    Mostofi, Navid
    Elliott, John O.
    ANNALS OF NEUROLOGY, 2007, 62 : S29 - S29
  • [26] Determining when to stop antiepileptic drug treatment
    Schachter, Steven C.
    CURRENT OPINION IN NEUROLOGY, 2018, 31 (02) : 211 - 215
  • [27] Visual field constriction and antiepileptic drug treatment
    Stefan, H
    Bernatik, J
    Knorr, HLJ
    NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, 2000, 7 (04) : 185 - 190
  • [28] PHOTOSENSITIVITY: THE ROLE OF DURATION OF ANTIEPILEPTIC DRUG TREATMENT
    Jocic-Jakubi, B.
    Jovanovic, M.
    Jankovic, Stankovic D.
    Trenite, Kasteleijn-Nolst D.
    EPILEPSIA, 2010, 51 : 54 - 54
  • [29] Antiepileptic drug treatment: Clinical considerations and concerns
    Brodtkorb, E
    GLUTAMATE SYNAPSE AS A THERAPEUTICAL TARGET: MOLECULAR ORGANIZATION AND PATHOLOGY OF THE GLUTAMATE SYNAPSE, 1998, 116 : 395 - 406
  • [30] Antiepileptic drug treatment following temporal lobectomy
    Maher, J
    McLachlan, RS
    NEUROLOGY, 1998, 51 (01) : 305 - 307